15 Mar 2024 • A novel blood-based test has demonstrated the potential to improve screening adherence, detect colorectal cancer earlier, and reduce colorectal cancer–related mortality.

• The cell-free DNA (cfDNA) blood-based test was utilized for colorectal cancer (CRC) screening in a population eligible for screening.
• Results revealed an impressive 83% sensitivity for detecting CRC, with 87.5% sensitivity for early-stage (I-III) cancers.
• The test also demonstrated a high specificity of 90% for detecting advanced neoplasia, with a sensitivity of 13% for advanced precancerous lesions.

Source: NEJM | Read full story